Takeda is taking care of its adopted home. The Japanese pharma has extended its longstanding partnership with the nonprofit ...

As Gilead Sciences awaits the progression of California state litigation over its alleged delay of safer HIV drugs, the ...

Once hyped as a potential blockbuster medicine for metabolic-associated steatohepatitis (MASH), Ipsen and Genfit’s ...

Amid a recent biopharma M&A resurgence, one major player plans to stay out of the waters after making multiple recent ...

Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower ...

AstraZeneca’s booming oncology business has won over cancer patient groups. Having languished down the leaderboard in the ...

More than 1 million of the drugmaker’s internal documents were made public in the initial bankruptcy case, the 2022 ...